804; Abstract A7741]. A Prospective Evaluation of Tolerability of Niraparib Dosing Based Upon Baseline Body Weight and Platelet Count: Blinded Pooled Interim Safety Data From the PRIMA/ENGOT OV26/GOG 3012 Study, 3. 1. 7. Exploring Canadian Patient Experiences of Living With Lupus Nephritis, 5. ORAL FEATURED POSTER: Interim Analysis of the Immune-Related Endpoints of the Mismatch Repair Deficient (dMMR) and Proficient (MMRp) Endometrial Cancer Cohorts From the GARNET Study, 1. NY-ESO-1 based immunotherapy of cancer: current perspectives. Lan Y, Zhang D, Xu C, et al. Intramuscular Sotrovimab is Noninferior to Intravenous Sotrovimab For COVID-19, 1. POSTER: A report of the postmarketing spontaneous safety data over 24 years for GSK?s measles-mumps-rubella (MMR) vaccine. [Oral presentation available here; Abstract A4212]. POSTER: RSVPreF3 OA Candidate Vaccine Safety Presentation. 1. Chronic Kidney Disease and Anemia Questionnaire (CKD-AQ): A Reliable and Sound PRO Measure for use in Patients with Anemia of CKD? Nathan R, Boulet L-P, Kerstjens HA, et al. Oral presentation. Real-World Effectiveness Of Mepolizumab In Patients With Allergic And Non-Allergic Asthma. Exploring Use of Regular ICS/LABA Dosing in Moderate to Severe Asthma Among Physicians: Results from the Asthma Patients? When expanded it provides a list of search options that will switch the search inputs to match the current selection. las molestias. POSTER: VOCAL (Views of Ovarian Cancer patients-how maintenance therapy Affects their Lives) study: patient preference for treatment formulation and administration (IGCS 2022), 2. Zhang S, Czira A, Harley J, et al. * Works in partnership with country teams to create and then implement global medical . 2. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: ENGOT-EN6/GOG-3031/ NSGO-RUBY: A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab + Carboplatin? 1-800-822-7967. Demographic and clinical characteristics of patients experiencing on-treatment exacerbations, on-treatment death or premature study treatment withdrawal: The IMPACT Trial. Encore: Open-label Pilot Study of Genetically Engineered NY-ESO-1?Specific T Cells (GSK3377794) Alone or in Combination With Pembrolizumab in Relapsed/Refractory Multiple Myeloma [Publication only], Pilot Neoadjuvant Study of Niraparib in HER2-Negative, BRCA-Mutated Resectable Breast Cancer, 1. P1445. [Poster No. Ramesh N, Hegewald M, Maselli DJ, et al. Cole AL, Moretz C, Mu G, et al. 6. ORAL FEATURED POSTER: Efficacy of Niraparib by Timing of Surgery and Residual Disease: A Post-Hoc Analysis of Patients in the PRIMA/ENGOT-OV26/GOG-3012 Study, 5. Cancer Immunol Res. Bjermer L, Maltais F, Vogelmeier CF, et al. Insights From Allergy Practice. Watch the video here: gsk.to/3KQpI7P, Today is the day! A Population Study. POSTER: Kaye KS, Gupta V, Mulgirigama A, et al. 9. 3. Lymphocyte activation gene-3 (LAG-3) negatively regulates T-cell activity and, in combination with PD-1, mediates T-cell exhaustion. 1089; Abstract A3324]. POSTER: Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial (Presentation Is Not Available Due to Copyright), 4.POSTER: Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma (Presentation Posted With Permission), 5.POSTER: Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. 710; Abstract A1825]. POSTER: Healthcare Costs in Patients With Newly Diagnosed Advanced Ovarian Cancer Receiving Maintenance Treatment With Niraparib Monotherapy Or Active Surveillance In The United States, 2. Neutrophil extracellular traps and CXCR2 antagonism in chronic obstructive pulmonary disease: A pilot randomized control study. Meta-analysis From Two Phase 3 Trials. This is our global website, intended for visitors seeking information on GSK's worldwide business. [Poster No. The estimated total pay for a Medical Science Liaison at GSK is $234,850 per year. PUBLICATION ONLY: STING Agonist GSK3745417 Induces Apoptosis, Antiproliferation, and Cell Death in a Panel of Human AML Cell Lines and Patient Samples, 1.POSTER: Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study by the European Myeloma Network (Presentation Posted With Permission), 2. Stability Calculator, Contact Assessment of Peak Inspiratory Flow Rate in Patients With Chronic Obstructive Pulmonary Disease: Impact on Dose Delivery and Relationship With Response to Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy. NY-ESO-1?specific TCR?engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. POSTER: ENGOT-OV44/FIRST Study: A Randomized, Double-Blind, Adaptive, Phase 3 Study of Platinum-Based Chemotherapy (CT) Dostarlimab Followed by Niraparib Dostarlimab Maintenance as First-Line (1L) Treatment of Stage 3 or 4 OC, 2. 2. Demographics and Characteristics of Patients Who Initiate Biologics for Asthma. The Impact of Comorbid Nasal Polyps on Real-World Mepolizumab Effectiveness in Patients with Severe Asthma: Results from the REALITI-A Study. PUBLICATION ONLY: Standards of Care and Treatment Patterns Among Relapsed/Refractory Multiple Myeloma Patients Initiating Second- and Third-Line Therapies, 15. The Relationship Between Overall Survival (OS), Progression-Free Survival (PFS), and Objective Response Rate (ORR) in Immune Checkpoint Inhibitor Clinical Trials of Head and Neck Squamous Cell Carcinoma (HNSCC): A Systematic Review and Meta-analysis, 10. The information is not intended as medical advice. Bogart M, Bunner S, Johnson MG, et al. ORAL PRESENTATION: No Evidence of BCMA Expression Loss or Systemic Immune Impairment After Treatment With the BCMA-targeted Antibody-Drug Conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 Trials of Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 2. Epigenetics. Rescue Medication Use as an Indicator of Symptom Burden in Patients With COPD: A Post Hoc Analysis of the EMAX Trial. Blood. Se continui a visualizzare Dostarlimab is being investigated as a monotherapy in DNA mismatch repair?deficient cancers, including endometrial cancer, and in unselected populations in combination with other therapies. Search jobs Life at GSK Careers . P711; Abstract A1826]. Targeting B-cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. CAPTAIN Study: Association of moderate and severe asthma exacerbations with lung function and patient-reported outcomes in a large randomized phase III clinical trial. GSK is committed to the discovery and development of new vaccines and oncology and hematology compounds that leverage patient-driven science to deliver improved outcomes for more patients. P474; Abstract A3997]. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience, and knowledge of the individual patient. PRMT5 is overexpressed in multiple tumor types, including lymphoma and breast, lung, and bladder cancer, and regulates splicing, gene expression, and activation of p53. Tumor necrosis factor receptor superfamily, member 4 (OX40 [CD134]) is expressed by T cells during antigen-specific priming. POSTER: Early COVID-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab. [Poster No. Efficacy of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Number-Needed-to-Treat Analysis of the EMAX Trial. Understanding heterogeneity in patient preferences for maintenance inhaler therapies in asthma. Ferguson GT, Brown N, Compton C, et al. ORAL PRESENTATION: Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer, 1. Comparison of Peak Inspiratory Flow Rate Between Clinical Trial and Real-World Populations. Sign In. Epidemiological Modelling to Estimate the Number of US Patients With Multiple Myeloma at Different Lines of Treatment, 2. 1. Chronic Kidney Disease and Anemia Questionnaire (CKD-AQ): A Reliable and Sound PRO Measure for use in Patients with Anemia of CKD? Als u dit bericht blijft zien, stuur dan een e-mail POSTER: Belantamab Mafodotin detection by protein electrophoresis: Assessing interference for defining clinical response, 2. Domingo Ribas C, Pavord I, Price R, et al. preferences for treatments of anemia of chronic kidney disease: a qualitative study. Initiating Mepolizumab. Singh, AK et al. and Physicians? Real-World Benefits of Mepolizumab in Patients With Overlapping Allergic and Eosinophilic Endophenotypes: Post Hoc Analysis of REALITI-A by Omalizumab Eligibility (Poster No. DREAMM-2: Single-Agent Belantamab Mafodotin in Patients With RRMM?Outcomes by Prior Therapies [Poster not available for viewing due to copyright restrictions], 6. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. A phase 2/3, randomized, placebo-controlled study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer (TiP), 13. ?Trap?/Anti-PD-L1 Fusion Protein, Belantamab Mafodotin - Anti-BCMA Immunoconjugate, PRMT5 Inhibitor (GSK3326595) and Type I PRMT Inhibitor (GSK3368715). Prevalence of asthma and severe asthma in patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. and PD-L1, for Second-Line (2L) Treatment of Non-Small Cell Lung Cancer (NSCLC). Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. Nature. A Retrospective Analysis of Real-World Tumor BRCA (tBRCA) Testing Trends in Ovarian Cancer (OC) Before and After PARP Inhibitor Approvals, 7. ORAL PRESENTATION: Evolution of the Ovarian Cancer Treatment Paradigm, Including Maintenance Treatment, In the US and Europe: A Real-World Chart Review Analysis (2017?2020), 1. Youll have opportunities to work on challenging projects and assignments that will help you grow, thrive, and reach your full potential. 1. 61), 1. 2018;9:1-15. doi:10.3389/fi mmu.2018.01821. Time-Dependent Covariate Analysis of Hemoglobin Values ?on Risk of MACE in the ASCEND Trials. Goodall E, Wood R, Numbere B, et al. POSTER: Cobolimab with Dostarlimab and Docetaxel in Patients with Advanced Non-small Cell Lung Cancer (NSCLC): COSTAR Lung COSTAR, 2. P805; Abstract A7742]. Registered in England and Wales No. 10. 3. EU Medical Affairs Lead, Hematology. CAPTAIN Study: Treatable Traits and the Outcome of Treatment with Inhaled Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI Therapies in Patients with Uncontrolled Asthma, a Pre-specified Subgroup Analysis. Preliminary Safety, Efficacy, and PK/PD Characterization from GARNET, a Phase 1 Clinical Trial of the Anti-PD-1 Monoclonal Antibody, TSR-052, in Patients with Recurrent or Advanced MSI-H Endometrial Cancer, 4. PO2409, 3. 1. Full-Time. We're taking on some of the biggest healthcare challenges in . ?Post hoc Analyses of ASCEND-ND and ASCEND-D, 1. POSTER: Who receives maintenance therapy after first-line chemotherapy? Ison MG et al. A Phase 2, Single Arm, Open Label Study to evaluate the safety and efficacy of niraparib combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer following frontline platinum-based chemotherapy with bevacizumab (OVARIO), 5. Wenn Once-Daily Single-Inhaler Versus Twice-Daily Multiple-Inhaler Triple Therapy: Two Replicate Trials in Patients With Chronic Obstructive Pulmonary Disease (COPD). [Poster No. Change in nasal polyp size as an indicator of treatment response: SYNAPSE trial analysis? (Poster No. P699; Abstract A1814]. Oncotarget. The anti-tumor efficacy of TIM-3 blockade in a murine model of sarcoma, 1. Silver J, Steffens A, Chastek B, et al. Characteristics and Inpatient Outcomes of Hospitalized Patients with COVID-19 ? Mularski R, Wu B, Fuoco MJ, et al. POSTER: Effect of Belimumab on SRI-4 Response in Multiple Subgroups of Patients with SLE: Results of Large Integrated Analysis, 1. Efficacy and Safety of Mepolizumab in Hypereosinophilic Syndrome: a Phase III, Randomized, Placebo-Controlled Trial. Effect of Serostatus on the Efficacy of Sotrovimab in Preventing COVID-19 Progression, 2. Resistance analysis in the COMET-ICE study: sotrovimab treatment in participants with mild-to-moderate COVID-19. A Nationwide Multicentric Study, 4. GSK US Medical Affairs Scientific Director, Specialty Pipeline Durham, NC 30d+ $95K-$138K Per Year (Glassdoor est.) Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Asthma in the United States: A Population-Based Study.
Josey Wales Kill Count,
Renton Shooting Last Night,
Articles G